ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

By Peter Loftus Of DOW JONES NEWSWIRES Drug maker Bristol-Myers Squibb Co. (BMY) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas. Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries." The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing. Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA. U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement. Last year, Johnson & Johnson (JNJ) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein. Other drug makers--including Pfizer Inc. (PFE), Merck & Co. (MRK) and Eli Lilly & Co. (LLY)--also have been the subjects of federal inquiries regarding the FCPA. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
04/10/201409:43:48Merck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial...
04/10/201409:30:24Merck: Hepatitis C Drug Shows 98% Cure Rate in Trial
04/10/201409:09:09Merck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial
03/30/201408:46:34MARKET SNAPSHOT: Play-it-safe Stock Investors May Take Some Risk...
03/30/201408:44:49New Drugs to Lower Cholesterol Show Promise: Studies
03/28/201418:57:23Merck CEO Frazier: Consumer Unit Draws 'Substantial' Interest...
03/27/201409:44:41U.S. Hot Stocks: Hot Stocks to Watch
03/26/201416:30:44Merck, Glaxo Hold Off on Help With Affordable Care Act Copays
03/12/201415:50:24Glaxo Reports Positive Results from Asthma Drug Studies
03/12/201415:36:51GlaxoSmithKline Reports Positive Results from Asthma Drug Studies...
03/05/201414:00:05Merck, Bristol-Myers Report Positive Data
03/05/201413:50:39Merck, Bristol-Myers Report Positive Data on Investigational...
02/12/201418:27:22Merck's Sale of Consumer Business Could Fetch $10 Billion...
02/07/201417:50:50Merck to Settle Contraceptive Product Lawsuits
02/07/201417:30:19Merck to Settle Contraceptive Product-Liability Lawsuits
02/07/201411:50:13Merck to Pay $100 Million in Legal Settlement on Contraceptive...
02/05/201416:47:03MARKET SNAPSHOT: U.S. Stocks Fall; Data Stoke Fears Of Slowdown
02/05/201414:11:17MARKET SNAPSHOT: U.S. Stocks Eye Rebound; Dow Reverses Losses
02/05/201411:42:07MARKET SNAPSHOT: U.S. Stocks Fall To Session Lows After ISM...
02/05/201410:13:00MARKET SNAPSHOT: U.S. Stocks Open Lower On Weak ADP Report

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad